-DOCSTART- -X- O
Objective. -X- _ O
Heart -X- _ B-Patient
failure -X- _ I-Patient
( -X- _ I-Patient
HF -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
a -X- _ O
global -X- _ O
public -X- _ O
health -X- _ O
problem. -X- _ O
Early -X- _ O
literature -X- _ O
studies -X- _ O
manifested -X- _ O
that -X- _ O
Shenfu -X- _ B-Intervention
injection -X- _ I-Intervention
( -X- _ I-Intervention
SFI -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
most -X- _ O
commonly -X- _ O
used -X- _ O
traditional -X- _ O
Chinese -X- _ O
patent -X- _ O
medicine -X- _ O
for -X- _ O
HF -X- _ B-Patient
in -X- _ I-Patient
China. -X- _ I-Patient
This -X- _ O
article -X- _ O
intended -X- _ O
to -X- _ O
systematically -X- _ O
evaluate -X- _ O
the -X- _ O
efficacy -X- _ B-Outcome
and -X- _ I-Outcome
safety -X- _ I-Outcome
of -X- _ O
SFI -X- _ B-Intervention
for -X- _ O
HF. -X- _ B-Patient
Methods. -X- _ O
An -X- _ O
extensive -X- _ O
search -X- _ O
was -X- _ O
performed -X- _ O
within -X- _ O
6 -X- _ O
English -X- _ O
and -X- _ O
Chinese -X- _ O
electronic -X- _ O
database -X- _ O
up -X- _ O
to -X- _ O
November -X- _ O
2011. -X- _ O
Ninety-nine -X- _ O
randomized -X- _ O
controlled -X- _ O
trails -X- _ O
( -X- _ O
RCTs -X- _ O
) -X- _ O
were -X- _ O
collected -X- _ O
, -X- _ O
irrespective -X- _ O
of -X- _ O
languages. -X- _ O
Two -X- _ O
authors -X- _ O
extracted -X- _ O
data -X- _ O
and -X- _ O
assessed -X- _ O
the -X- _ O
trial -X- _ O
quality -X- _ O
independently. -X- _ O
RevMan -X- _ O
5.0.2 -X- _ O
was -X- _ O
used -X- _ O
for -X- _ O
data -X- _ O
analysis. -X- _ O
Results. -X- _ O
Compared -X- _ O
with -X- _ O
routine -X- _ O
treatment -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
device -X- _ O
support -X- _ O
, -X- _ O
SFI -X- _ B-Outcome
combined -X- _ I-Outcome
with -X- _ I-Outcome
routine -X- _ I-Outcome
treatment -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
device -X- _ I-Outcome
support -X- _ I-Outcome
showed -X- _ I-Outcome
better -X- _ I-Outcome
effect -X- _ I-Outcome
on -X- _ I-Outcome
clinical -X- _ I-Outcome
effect -X- _ I-Outcome
rate -X- _ I-Outcome
, -X- _ I-Outcome
mortality -X- _ I-Outcome
, -X- _ I-Outcome
heart -X- _ I-Outcome
rate -X- _ I-Outcome
, -X- _ I-Outcome
NT-proBNP -X- _ I-Outcome
and -X- _ I-Outcome
6-minute -X- _ I-Outcome
walk -X- _ I-Outcome
distance. -X- _ I-Outcome
Results -X- _ I-Outcome
in -X- _ I-Outcome
ultrasonic -X- _ I-Outcome
cardiography -X- _ I-Outcome
also -X- _ I-Outcome
showed -X- _ I-Outcome
that -X- _ I-Outcome
SFI -X- _ I-Outcome
combined -X- _ I-Outcome
with -X- _ I-Outcome
routine -X- _ I-Outcome
treatment -X- _ I-Outcome
improved -X- _ I-Outcome
heart -X- _ I-Outcome
function -X- _ I-Outcome
of -X- _ I-Outcome
HF -X- _ I-Outcome
patients. -X- _ I-Outcome
There -X- _ I-Outcome
were -X- _ I-Outcome
no -X- _ I-Outcome
significant -X- _ I-Outcome
difference -X- _ I-Outcome
in -X- _ I-Outcome
blood -X- _ I-Outcome
pressure -X- _ I-Outcome
between -X- _ I-Outcome
SFI -X- _ I-Outcome
and -X- _ I-Outcome
routine -X- _ I-Outcome
treatment -X- _ I-Outcome
groups. -X- _ I-Outcome
Adverse -X- _ I-Outcome
events -X- _ I-Outcome
were -X- _ I-Outcome
reported -X- _ I-Outcome
in -X- _ I-Outcome
thirteen -X- _ I-Outcome
trails -X- _ I-Outcome
with -X- _ I-Outcome
thirteen -X- _ I-Outcome
specific -X- _ I-Outcome
symptoms -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
no -X- _ I-Outcome
serious -X- _ I-Outcome
adverse -X- _ I-Outcome
effect -X- _ I-Outcome
was -X- _ I-Outcome
reported. -X- _ I-Outcome
Conclusion. -X- _ I-Outcome
SFI -X- _ I-Outcome
appear -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
effective -X- _ I-Outcome
for -X- _ I-Outcome
treating -X- _ I-Outcome
HF. -X- _ I-Outcome
However -X- _ O
, -X- _ O
further -X- _ O
rigorously -X- _ O
designed -X- _ O
RCTs -X- _ O
are -X- _ O
warranted -X- _ O
because -X- _ O
of -X- _ O
insufficient -X- _ O
methodological -X- _ O
rigor -X- _ O
in -X- _ O
the -X- _ O
majority -X- _ O
of -X- _ O
included -X- _ O
trials -X- _ O
. -X- _ O

